Bedtime Elinzanetant Tied to Better Morning Alertness in Menopause Trial Review
A pooled post-hoc analysis of two phase III trials found that bedtime elinzanetant, a nonhormonal NK receptor antagonist for menopausal hot flashes, did not worsen next-day sleepiness. Participants taking the drug had modestly greater improvements in sleepiness scores than those on placebo, especially in the morning. The researchers said the findings suggest the treatment is unlikely to impair daytime functioning.
The review pooled OASIS I and OASIS II, two phase III trials of elinzanetant, a dual NK1/NK3 blocker approved for moderate-to-severe menopausal hot flashes. Bedtime dosing is recommended, so researchers examined whether sleep benefits carried into next-day grogginess.
Sleepiness was tracked on a 0–4 scale across morning, afternoon, and evening. Baseline PROMIS sleep-disturbance scores indicated moderate disturbance; at 12 weeks, the drug group improved by 10.7 points versus 5.3 with placebo. An earlier phase I driving simulation found no clinically meaningful next-morning residual effect.
For menopausal women bothered by hot flashes and poor sleep, a nonhormonal option that does not appear to add morning drowsiness could support daily work, driving, and caregiving. Clinicians may find the pooled data reassuring when discussing bedtime dosing, though the analysis is exploratory and cannot prove real-world functioning benefits. Broader uptake could matter for people seeking alternatives to hormonal therapy, but cost, access, and individual response may shape who benefits.